HOME
Leading the way to a cure

PRESS RELEASES

Alliance For Lupus Research And Pfizer’s Centers For Therapeutic Innovation Announce Novel Research Collaboration With Leading Academic Medical Centers

November 7, 2012


   

For immediate release:

                                                                    Pfizer Inc.
Lauren Starr
(646) 761-0965

                                                                    Alliance for Lupus Research
Courtney Love
(646) 884-6069

Alliance For Lupus Research And Pfizer’s Centers For Therapeutic Innovation Announce Novel Research Collaboration With Leading Academic Medical Centers

NEW YORK, N.Y., November 7 – Alliance for Lupus Research (ALR) and Pfizer’s Centers for Therapeutic Innovation (CTI) are partnering to discover new therapies for patients living with lupus.  As part of this first-of-its-kind collaboration in lupus, ALR and CTI will co-fund novel translational research projects driven by leading academic medical centers within the CTI network.

The partnership is designed to enable joint project teams, consisting of Pfizer scientists and academic researchers, to translate novel scientific ideas into therapeutics that address unmet medical need.  “Bringing new treatment options to people with lupus is our priority at ALR.  We are thrilled to be working with CTI.  The potential to quickly move promising therapeutics from the lab into Phase I clinical trials is something we are all very excited about,” said Ken Farber, president, ALR.

The CTI and ALR collaboration represents an evolution of the R&D ecosystem that CTI is designed to achieve, in which industry works in close partnership with academia, non-profit organizations, and other stakeholders to advance research and benefit patients.  “It is clear that ALR shares CTI’s entrepreneurial spirit and quest for innovation, and we are excited to be partnering with ALR to find new treatment options for lupus," said Anthony J. Coyle, vice president & chief scientific officer, CTI.

This new collaboration maintains the key partnership attributes and principles that CTI has established with its network of leading academic medical centers.  The parties anticipate that research projects may be commenced in the first half of 2013.

About Lupus

Systemic Lupus Erythematosus (SLE, or lupus) is a chronic autoimmune disease that can affect the joints and almost every major organ in the body, including the heart, kidneys, skin, lungs, and brain.  As many as 1.5 million people in theUnited Stateshave lupus, which affects mostly women during their childbearing years, though men and children can have the disease as well. Lupus is three times more common in African-American women than in Caucasian women, and is also more prevalent in women of Latino, Asian, and Native American descent.

About the ALR

The Alliancefor Lupus Research (ALR) is a national voluntary health organization dedicated to finding better treatments and ultimately preventing and curing systemic lupus erythematosus (SLE, or lupus), a debilitating autoimmune disease.  The organization is based in New York Cityand chaired by Robert Wood Johnson IV, principal owner of the New York Jets.  Since its founding in 1999, the ALR has given more money to lupus research than any non-governmental agency in the world.  The ALR board of directors funds all administrative and fundraising costs, allowing one hundred percent of all donations from the public, and the proceeds of its signature grassroots fundraising program, “Walk with Us to Cure Lupus,” to go directly to support research programs.  For more information about ALR, visit www.lupusresearch.org.

About Pfizer’s CTI

The Centers for Therapeutic Innovation (CTI) is an entrepreneurial Research Unit at Pfizer, Inc. dedicated to the establishment of partnerships with Academic Medical Centers (AMCs) to transform research and development through a focus on translational medicine.  CTI is an open innovation network with 21 leading AMCs focused on joint discovery and development of therapeutics, from early research through clinical proof-of-mechanism in humans.  This model offers leading investigators the resources to pursue potential scientific and clinical breakthroughs by providing access to select Pfizer compound libraries, proprietary screening methods and antibody development technologies that are directly relevant to the investigators' work.  The aim is to translate scientific ideas into clinically differentiated candidates ready for evaluation in a stratified patient population.  CTI laboratories include Pfizer employees working side-by-side with leading investigators and post-doctoral researchers from the AMCs.  The CTI collaborative model effectively and efficiently combines the best ideas, research and expertise of the AMCs with Pfizer's experience, technology and resources.  For more information about CTI, visit http://www.pfizer.com/research/rd_works/centers_for_therapeutic_innovation.jsp

PFIZER DISCLOSURE NOTICE: The information contained in this release is as of November 7, 2012. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. 

This release contains forward-looking information that involves substantial risks and uncertainties about potential new therapies for the treatment of lupus that might result from the collaboration between CTI and ALR. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications that may be filed for any such therapies as well as their decisions regarding labeling and other matters that could affect their availability or commercial potential; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and in its reports on Form 10-Q and Form 8-K.

 # # # # #

 


Alliance For Lupus Research And Pfizer’s Centers For Therapeutic Innovation Announce Novel Research Collaboration With Leading Academic Medical Centers

November 7, 2012


   

For immediate release:

                                                                    Pfizer Inc.
Lauren Starr
(646) 761-0965

                                                                    Alliance for Lupus Research
Courtney Love
(646) 884-6069

Alliance For Lupus Research And Pfizer’s Centers For Therapeutic Innovation Announce Novel Research Collaboration With Leading Academic Medical Centers

NEW YORK, N.Y., November 7 – Alliance for Lupus Research (ALR) and Pfizer’s Centers for Therapeutic Innovation (CTI) are partnering to discover new therapies for patients living with lupus.  As part of this first-of-its-kind collaboration in lupus, ALR and CTI will co-fund novel translational research projects driven by leading academic medical centers within the CTI network.

The partnership is designed to enable joint project teams, consisting of Pfizer scientists and academic researchers, to translate novel scientific ideas into therapeutics that address unmet medical need.  “Bringing new treatment options to people with lupus is our priority at ALR.  We are thrilled to be working with CTI.  The potential to quickly move promising therapeutics from the lab into Phase I clinical trials is something we are all very excited about,” said Ken Farber, president, ALR.

The CTI and ALR collaboration represents an evolution of the R&D ecosystem that CTI is designed to achieve, in which industry works in close partnership with academia, non-profit organizations, and other stakeholders to advance research and benefit patients.  “It is clear that ALR shares CTI’s entrepreneurial spirit and quest for innovation, and we are excited to be partnering with ALR to find new treatment options for lupus," said Anthony J. Coyle, vice president & chief scientific officer, CTI.

This new collaboration maintains the key partnership attributes and principles that CTI has established with its network of leading academic medical centers.  The parties anticipate that research projects may be commenced in the first half of 2013.

About Lupus

Systemic Lupus Erythematosus (SLE, or lupus) is a chronic autoimmune disease that can affect the joints and almost every major organ in the body, including the heart, kidneys, skin, lungs, and brain.  As many as 1.5 million people in theUnited Stateshave lupus, which affects mostly women during their childbearing years, though men and children can have the disease as well. Lupus is three times more common in African-American women than in Caucasian women, and is also more prevalent in women of Latino, Asian, and Native American descent.

About the ALR

The Alliancefor Lupus Research (ALR) is a national voluntary health organization dedicated to finding better treatments and ultimately preventing and curing systemic lupus erythematosus (SLE, or lupus), a debilitating autoimmune disease.  The organization is based in New York Cityand chaired by Robert Wood Johnson IV, principal owner of the New York Jets.  Since its founding in 1999, the ALR has given more money to lupus research than any non-governmental agency in the world.  The ALR board of directors funds all administrative and fundraising costs, allowing one hundred percent of all donations from the public, and the proceeds of its signature grassroots fundraising program, “Walk with Us to Cure Lupus,” to go directly to support research programs.  For more information about ALR, visit www.lupusresearch.org.

About Pfizer’s CTI

The Centers for Therapeutic Innovation (CTI) is an entrepreneurial Research Unit at Pfizer, Inc. dedicated to the establishment of partnerships with Academic Medical Centers (AMCs) to transform research and development through a focus on translational medicine.  CTI is an open innovation network with 21 leading AMCs focused on joint discovery and development of therapeutics, from early research through clinical proof-of-mechanism in humans.  This model offers leading investigators the resources to pursue potential scientific and clinical breakthroughs by providing access to select Pfizer compound libraries, proprietary screening methods and antibody development technologies that are directly relevant to the investigators' work.  The aim is to translate scientific ideas into clinically differentiated candidates ready for evaluation in a stratified patient population.  CTI laboratories include Pfizer employees working side-by-side with leading investigators and post-doctoral researchers from the AMCs.  The CTI collaborative model effectively and efficiently combines the best ideas, research and expertise of the AMCs with Pfizer's experience, technology and resources.  For more information about CTI, visit http://www.pfizer.com/research/rd_works/centers_for_therapeutic_innovation.jsp

PFIZER DISCLOSURE NOTICE: The information contained in this release is as of November 7, 2012. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. 

This release contains forward-looking information that involves substantial risks and uncertainties about potential new therapies for the treatment of lupus that might result from the collaboration between CTI and ALR. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications that may be filed for any such therapies as well as their decisions regarding labeling and other matters that could affect their availability or commercial potential; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and in its reports on Form 10-Q and Form 8-K.

 # # # # #

 



1.5 million

people in the U.S. have Lupus.

90 million

dollars committed to lupus research by the Alliance for Lupus Research.


We're walking across the United States to raise awareness and funds for lupus research.

Can't make it? Join our National Virtual Walk to participate anytime, anywhere.


Show your support by visiting the Alliance for Lupus Research online store. Discover the perfect gift, or prepare for a walk with our selection of apparel and accessories.

Powered by Convio
nonprofit software